Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
SAN FRANCISCO, Nov. 30, 2016 -- Hagens Berman Sobol Shapiro LLP alerts investors in Cempra Inc. (NASDAQ:CEMP) to an expanded class period and reminds them of the January 3, 2017 Lead Plaintiff deadline.
The new class period includes investors who purchased or otherwise acquired Cempra shares between October 22, 2015 and November 1, 2016. If you purchased or acquired Cempra shares during the class period and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/CEMP
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
Cempra allegedly failed to disclose to investors that its drug, solithromycin, created significant health risks to users.
On November 2, 2016 the Food and Drug Administration reported on its website that solithromycin may cause a serious rise in liver enzymes and result in hepatotoxicity. Disclosure of the FDA’s report drove the price of Cempra shares down approximately 60% to close at $7.30 per share that day.
On November 3, 2016 Benzinga quoted a stock analyst who stated: “[w]e had previously argued liver enzyme elevations alone would be a navigable subject matter – but the revelation of a previously-undisclosed instance of definitive solithromycin mediated drug-induced liver injury…now fundamentally challenges this hypothesis.”
“We’re evaluating the FDA’s material and the results of the FDA’s advisory panel meeting in the context of the Company’s and management’s public statements about solithromycin,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Cempra should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
